SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is drawing significant attention as crude oil prices surge towards $90-$100 a barrel amid escalating Middle East tensions, fueling community discussions about a potential massive short squeeze reminiscent of its historic moves during similar geopolitical events.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing a significant surge, driven by escalating geopolitical tensions highlighting the critical need for defense drone technology, particularly with widespread anticipation of upcoming contracts from the U.S. military's "Drone Dominance" program. The community is actively discussing the company's strong positioning with American-made solutions and potential short squeeze dynamics amidst heavy trading volume.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is sharply rising as the escalating U.S.-Iran conflict impacts oil supplies, with reports of tanker attacks and disruptions in the critical Strait of Hormuz. The community is keenly discussing the 'war premium,' with many anticipating crude to break $100-$150 per barrel if geopolitical tensions and supply constraints persist, while others debate the sustainability of the rally.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is in focus after delivering a strong earnings report and an upbeat multi-year outlook, propelled by robust demand for its AI data center connectivity and custom silicon solutions. The semiconductor firm is garnering widespread analyst upgrades and community discussion on its pivotal role in the AI infrastructure buildout, amidst broader market fluctuations.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as escalating geopolitical tensions in the Middle East and concerns over the current administration's economic policies fuel community discussions about rising oil prices, job impacts, and high-profile leadership changes.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

A $27 million Department of War grant to expand domestic antimony production is propelling United States Antimony Corp., a critical mineral producer vital for defense, amid escalating global tensions. The community is keenly focused on its upcoming NYSE uplisting, anticipating significant institutional interest due to UAMY's strategic position as the sole major antimony supplier outside of China and Russia.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

The acquisition of Day One Biopharmaceuticals by Servier for $2.5 billion, or $21.50 per share, is driving conversation as shareholders celebrate the significant premium and trapped shorts. This deal strengthens Servier's rare oncology portfolio and has the biotech community actively speculating on the next M&A target.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Recent significant orders, including a $20 million initial contract for a national autonomous border protection system and additional counter-drone sales, are driving conversation around Ondas Inc. The community anticipates strong upcoming earnings amid escalating global demand for defense and drone technology, yet frustration persists over perceived stock manipulation and "delta hedging" that is reportedly suppressing price action.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is gaining attention as its Quantum Leap Energy subsidiary solidifies partnerships for advanced nuclear fuel, vital for future energy demands including AI, and provides promising updates on its Renergen Helium project. However, community discussions reflect impatience over delays in core isotope production and concerns regarding management's diversified investment strategy.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid an unexpected weak jobs report and escalating geopolitical tensions driving oil prices higher, sparking community debate over potential stagflation. Investors are sharply divided between fears of further market declines and expectations of a "V" shaped recovery from critical support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of "Hold" from Analysts

Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. One investment...

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -6.99% and -1.53%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Korro Bio (NASDAQ:KRRO) Stock Rating Upgraded by Clear Str

Clear Str upgraded shares of Korro Bio from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Korro Bio (NASDAQ:KRRO) Upgraded to "Outperform" at William Blair

William Blair upgraded Korro Bio from a "market perform" rating to an "outperform" rating in a report on Tuesday...

Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of "Hold" by Brokerages

Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have earned an average recommendation of "Hold" from the ten research firms that are presently covering the stock, MarketBeat reports. One...

HC Wainwright Brokers Lower Earnings Estimates for Korro Bio

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - HC Wainwright reduced their Q2 2026 earnings estimates for shares of Korro Bio in a research report issued to clients and investors on Thursday, January...

Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE

Korro Bio (NASDAQ:KRRO) used its Analyst Day to outline the rationale and development plans for KRRO-121, an RNA-editing therapeutic candidate the company believes could provide a new approach to...

<ul class="summary-bullets"><li>H.C. Wainwright said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."</li><li>Piper Sandler said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success.</li><li>Oppenheimer upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target.</li></ul>Shares of Korro Bio Inc. (KRRO) jumped 13% on Thursday after multiple analysts upgraded the stock on optimism about the company’s new development candidate KRRO-121.Korro is now looking to study the drug in the treatment of hyperammonemia. The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for the candidate.<h2 class="st-heading-2">Analysts Chime In</h2>H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, according to TheFly. The firm said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."Korro shares are trading near a zero enterprise value, the analyst told investors in a research note. H.C. Wainwright believes KRRO-121 is not a read-through from KRRO-110,"so this is a truly independent shot on goal."Piper Sandler analyst Yasmeen Rahimi on Wednesday also upgraded Korro Bio to ‘Overweight’ from ‘Neutral’ with a price target of $30, up from $11. Piper said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success, it said.The firm is bullish ahead of KRRO-121's new drug filing in the second half of 2026, saying there is a "clear precedence for a regulatory path."Oppenheimer also upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target. The firm believes the company's probability of success is now reset and that KRRO-121 offers a fresh, interesting story wherein RNA editing can thrive. The firm sees potential for significant upside.<h2 class="st-heading-2">Pivot From KRRO-110</h2>In November, Korro said that in its <a href="https://stocktwits.com/news-articles/markets/equity/korro-bio-stock-crashes-over-75-after-hours-on-drug-failure-downgrades-and-layoffs/cLPBNsbREdA">trial</a> evaluating KRRO-110 in the genetic disorder called Alpha-1 Antitrypsin Deficiency (AATD), it achieved functional protein production with a single administration, but it did not achieve the protein levels projected based on preclinical data.The lower-than-expected results prompted a 34% reduction in working and the company subsequently opted KRRO-121 as its next development candidate, for the potential treatment of patients with hyperammonemia.Hyperammonemia is a critical metabolic condition defined by abnormally elevated blood ammonia levels, commonly resulting from liver failure (cirrhosis) or inherited urea cycle disorders. It causes acute, severe neurological impairment—including encephalopathy, seizures, coma, and cerebral edema—and requires immediate medical intervention to prevent fatal brain damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KRRO stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that a strong momentum setup is shaping up, adding that buyers are defending these levels and pushing higher.<stembedurl>https://www.stocktwits.com/topstockalerts/message/643304339</stembedurl><a href="https://stocktwits.com/symbol/KRRO">KRRO shares</a> have dropped 60% in the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-administration-reportedly-ready-to-lay-out-crypto-law/cmyikhjR41I">Trump Administration Reportedly Ready To Lay Out Crypto Rules</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?

The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121. 

Equity

The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121. 


Korro Bio (NASDAQ:KRRO) Shares Down 5.9% - Here's What Happened

Korro Bio (NASDAQ:KRRO) Stock Price Down 5.9% - What's Next...

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Current Price	$10.80
Prev Close	$10.95
Open	$10.85
Dividend Yield	0.00%
50-Day Moving Average	$10.48
Beta	2.57
Avg. Volume	159,381.89
PE Ratio	-1.16

52-Week High	$55.89
52-Week Low	$5.20
Market Capitalization	$103.12M
EPS (Annual)	-$9.37
Price to Book	1.04
Revenue Per Employee	$21,836.54

KRRO
Korro Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KRRO News

KRROKorro Bio Inc